Canine Blood Pressure Management: ARBs and Cardiovascular Medications for Dogs Across the UK — Semintra, Telmisartan, Losartan and Proven Kidney Protection Strategies (2026)
Published on Friday, 21 August 2026
Managing elevated blood pressure and chronic kidney disease in dogs requires careful consideration of pharmaceutical options, and angiotensin receptor blockers have emerged as a cornerstone therapy in contemporary veterinary practice. Unlike ACE inhibitors, ARBs work through a distinct mechanism to reduce systemic vascular resistance whilst protecting renal function and minimising proteinuria in dogs of all ages and sizes. UK veterinary practices increasingly advocate for ARB-based protocols when dogs present with resistant hypertension, progressive proteinuric nephropathy, or when previous ACE inhibitor therapy has proven inadequate. This comprehensive guide explores five evidence-based treatments that UK veterinarians recommend, including Semintra—the gold-standard licensed telmisartan formulation—alongside bespoke compounded preparations and complementary ACE inhibitor alternatives. Whether your dog requires immediate blood pressure intervention, long-term renal protection, or a tailored switch from conventional therapy, understanding the distinctions between these medications ensures informed decision-making in partnership with your veterinary team. We examine efficacy data, practical dosing considerations specific to the UK pharmaceutical landscape, palatability profiles that matter for daily administration, and the monitoring protocols your vet will employ to ensure optimal outcomes.
Top Picks Summary
Semintra Telmisartan Oral Solution for Cats
Semintra delivers telmisartan, a true ARB formulation in an oral solution that allows fine dose titration and practical off‑label use in dogs for targeted RAAS blockade to protect heart and kidneys. Its liquid format and direct AT1 receptor antagonism distinguish it from ACE inhibitor tablets on this list, offering a technical advantage in dosing precision and often a lower incidence of ACE‑inhibitor‑associated side effects; financially it can be more cost‑effective for weight‑based titration compared with multiple tablet products. As the only dedicated telmisartan product here, it is the primary ARB option veterinarians consider alongside ACE inhibitor and pimobendan regimens in the UK (2025).
Cardalis (Benazepril/Spironolactone) Chewable Tablets for Dogs
Cardalis combines an ACE inhibitor with a mineralocorticoid antagonist in a palatable chewable, offering combined RAAS inhibition and aldosterone blockade to address both neurohormonal activation and fluid retention in canine cardiac disease. Compared with benazepril alone (Fortekor) it provides broader pharmacologic coverage, and while it does not provide ARB‑class antagonism like telmisartan (Semintra), its fixed‑dose convenience and formulation can improve compliance; it typically carries a price premium versus generics but can reduce the need for multiple separate prescriptions. Clinicians often choose Cardalis for dogs needing dual RAAS modulation, using it alongside or before adding pimobendan (Vetmedin) depending on haemodynamic needs.
Fortekor Benazepril Tablets for Dogs and Cats
Fortekor (benazepril) is a well‑established ACE inhibitor widely used as first‑line RAAS modulation for canine heart and chronic kidney conditions, valued for its extensive clinical familiarity and often lower cost due to generic availability. Technically it offers proven ACE blockade but lacks the direct angiotensin II receptor antagonism of ARBs like telmisartan (Semintra) and does not address aldosterone escape the way combination products (Cardalis, Prilactone) do; financially it is frequently the most economical choice for long‑term monotherapy. For UK veterinarians in 2025, Fortekor remains a backbone option that may be combined with spironolactone or pimobendan when disease progresses.
Prilactone (Benazepril/Spironolactone) Flavoured Tablets for Dogs
Prilactone pairs benazepril with spironolactone in a flavoured tablet designed to ease administration while delivering both ACE inhibition and aldosterone antagonism to control fluid overload and remodelling. It competes directly with Cardalis as a combination ACE/aldosterone product but often positions itself as a cost‑conscious, palatable alternative to help adherence; unlike Semintra (telmisartan) it is not an ARB, so choice depends on whether direct AT1 blockade or ACE inhibition plus mineralocorticoid antagonism better suits the patient. Vets commonly select Prilactone for dogs needing consolidated therapy to reduce pill burden while preserving comprehensive RAAS control.
Vetmedin Pimobendan Chewable Tablets for Dogs
Vetmedin (pimobendan) is an inodilator that improves cardiac contractility and reduces cardiac workload, making it a market‑leading symptomatic therapy for canine congestive heart failure and a frequent companion to RAAS modulators rather than a direct ARB or ACE alternative. Technically complementary to telmisartan and benazepril products — it addresses haemodynamic support while ARBs/ACE inhibitors modulate neurohormonal drivers — and its strong clinical track record often justifies the cost in patients with systolic dysfunction. In the 2025 UK veterinary setting Vetmedin is therefore positioned as a cornerstone heart failure drug that is typically used together with an ARB or ACE inhibitor for holistic management.
These medications represent the most clinically robust options available through UK veterinary channels, combining demonstrated efficacy in controlling canine hypertension with favourable safety profiles when appropriately monitored. Each offers distinct advantages: licensed formulations provide pharmaceutical quality assurance, compounded preparations enable bespoke dosing, and the range ensures your vet can tailor therapy to your individual dog's requirements.
Understanding Angiotensin Receptor Blockers in Canine Medicine
Angiotensin receptor blockers function by selectively blocking AT1 receptors on vascular smooth muscle and renal tissue, preventing vasoconstriction and aldosterone release without inhibiting bradykinin metabolism—a key distinction from ACE inhibitors that occasionally causes adverse effects. In dogs with chronic kidney disease, ARBs reduce glomerular hyperfiltration and proteinuria through haemodynamic and anti-inflammatory mechanisms. British veterinary nephrology increasingly recognises ARBs as either first-line therapy or superior alternatives when ACE inhibitors have failed to achieve adequate blood pressure control or proteinuria reduction.
ARBs selectively block angiotensin II AT1 receptors, reducing blood pressure through different pathways than ACE inhibitors
Semintra is the only licensed veterinary ARB in the UK, providing pharmaceutical quality assurance and established dosing protocols
Compounded telmisartan and losartan preparations allow individualised dosing for dogs of varied weights and kidney function
ARBs demonstrate particular benefit in proteinuric kidney disease, often reducing urinary protein excretion more effectively than ACE inhibitors alone
Combination therapy with ACE inhibitors may provide synergistic renin-angiotensin system blockade in resistant cases
Blood pressure monitoring, baseline and periodic renal panels, and electrolyte assessments are essential during ARB therapy
Potential adverse effects include hyperkalaemia, azotaemia worsening, and hypotension—requiring veterinary oversight throughout treatment
ARBs are contraindicated in pregnant bitches and dogs with bilateral renal artery stenosis, though such conditions are rare in canine practice
Frequently Asked Questions
Which product is best for dog kidney proteinuria?
For dog kidney proteinuria with RAAS targeting, Semintra (Telmisartan) oral solution is the closest match, since it delivers telmisartan as a true ARB in a liquid once-daily format for accurate dose titration and veterinarian-prescribed proteinuria reduction; rating 4.5.
What dosing and receptor mechanism does Semintra use?
Semintra (Telmisartan) is a telmisartan oral solution designed for liquid, once-daily dosing that enables accurate titration, and it works via direct AT1 receptor antagonism; rating 4.5.
Is Semintra (telmisartan) licensed for dogs in the UK?
No. Semintra is licensed in the UK for cats (feline chronic kidney disease and hypertension), and telmisartan has no dog-specific licence in the UK. Because it is the only veterinary ARB available, vets may prescribe it off-label for dogs under the prescribing cascade when they judge a clinical benefit for proteinuric kidney disease or hypertension. The other four products here (Cardalis, Fortekor, Prilactone, Vetmedin) are not ARBs — they are ACE inhibitor combinations or an inodilator.
How does Cardalis pricing compare to simpler options?
Cardalis is indicatively priced around £40-80, versus roughly £20-60 for benazepril monotherapy (Fortekor) and £30-70 for the Prilactone benazepril/spironolactone combination. Cardalis is rated 4.2 and combines benazepril with spironolactone in chewable tablets for dual-action ACE and aldosterone blockade; confirm current pricing and suitability with your vet or pharmacy.
Conclusion
Selecting the right cardiovascular medication for your dog represents one of the most impactful health decisions you can make as a responsible owner. The five options detailed here—Semintra 10mg/mL Oral Solution, Telmisartan Compounded Oral Suspension, Losartan Compounded Tablets, Benazepril HCl Tablets, and Enalapril Maleate Tablets—reflect the spectrum of contemporary UK practice, from licensed proprietary formulations to individualised compounded therapies and established ACE inhibitor benchmarks. Semintra remains the preferred first-line choice when veterinary-labelled telmisartan is clinically appropriate and accessible; compounded alternatives provide flexibility for dogs requiring precise dose titration or those with specific palatability needs; whilst benazepril and enalapril continue to serve valuable roles in multimodal hypertension management. Your veterinary surgeon will weigh factors including your dog's specific diagnosis, concurrent medications, renal function markers, and tolerance profile to recommend the most suitable therapy. We encourage you to return with specific clinical questions or explore additional resources through our site, and always prioritise direct consultation with your veterinary team for treatment decisions bespoke to your dog's health needs.